Literature DB >> 16339615

Suicidal ideation and pharmacotherapy among STEP-BD patients.

Joseph F Goldberg1, Michael H Allen, David A Miklowitz, Charles L Bowden, Carrie J Endick, Cheryl A Chessick, Stephen R Wisniewski, Sachiko Miyahara, Kemal Sagduyu, Michael E Thase, Joseph R Calabrese, Gary S Sachs.   

Abstract

OBJECTIVE: Little is known about the effects of lithium on suicidal ideation or about the possible antisuicidal effects of divalproex, second-generation antipsychotics, or antidepressants among persons with bipolar disorder.
METHODS: Using a cross-sectional design, the authors examined patterns of psychotropic drug use relative to suicidal ideation among 1,000 patients with bipolar disorder in the National Institute of Mental Health's Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).
RESULTS: The presence of suicidal ideation was similar between patients who were taking any lithium and those who were not (22.2 percent and 25.8 percent, respectively) and between those who were taking any divalproex and those who were not (20.3 percent and 21.5 percent). Suicidal ideation was significantly more prevalent among patients who were taking a second-generation antipsychotic than those who were not (26 percent and 17 percent) and those who were taking an antidepressant and those who were not (25 percent and 14 percent). After other variables had been controlled for, lithium prescriptions were significantly more common among patients who had suicidal ideation.
CONCLUSIONS: Among patients with bipolar disorder who have suicidal ideation, antidepressants and second-generation antipsychotics appear to be prescribed by community practitioners more often than other medications, with lithium reserved for those with more severe illness characteristics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339615     DOI: 10.1176/appi.ps.56.12.1534

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  5 in total

Review 1.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

2.  Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.

Authors:  Diego Hidalgo-Mazzei; Michael Berk; Andrea Cipriani; Anthony J Cleare; Arianna Di Florio; Daniel Dietch; John R Geddes; Guy M Goodwin; Heinz Grunze; Joseph F Hayes; Ian Jones; Siegfried Kasper; Karine Macritchie; R Hamish McAllister-Williams; Richard Morriss; Sam Nayrouz; Sofia Pappa; Jair C Soares; Daniel J Smith; Trisha Suppes; Peter Talbot; Eduard Vieta; Stuart Watson; Lakshmi N Yatham; Allan H Young; Paul R A Stokes
Journal:  Br J Psychiatry       Date:  2018-12-06       Impact factor: 10.671

3.  Heterogeneity of psychosocial functioning in patients with bipolar disorder: Associations with sociodemographic, clinical, neurocognitive and biochemical variables.

Authors:  Zhengling Ba; Minhua Chen; Jiulan Lai; Yingtao Liao; Hengying Fang; Dali Lu; Yingjun Zheng; Kunlun Zong; Xiaoling Lin
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

4.  The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy.

Authors:  Cesario Bellantuono; Alessandra Barraco; Andrea Rossi; Iris Goetz
Journal:  BMC Psychiatry       Date:  2007-07-19       Impact factor: 3.630

5.  Antiepileptic drugs and suicide-related outcomes in bipolar disorder: A descriptive review of published data.

Authors:  Charles F Caley; Emily Perriello; Julia Golden
Journal:  Ment Health Clin       Date:  2018-04-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.